Cerebral cavernous malformations (CCM) are characterized by thinwalled, enlarged, multi-chambered and leaky vascular lesions of the central nervous system. Found at an estimated rate of 0.5% in the general population, CCM-bearing patients develop symptoms ranging from headaches, numbness and seizures, to haemorrhagic stroke. CCM development has been linked to independent loss of function mutations in 3 genes: KRIT1 (CCM1), CCM2 and CCM3 (PDCD10). 1, 2 However, despite the identification of several molecular targets affected by the loss of CCM proteins, the pathogenesis of CCM remains unclear. Furthermore, differences in phenotype in patients 3, 4 and models 5 with loss of function for these three genes also raise questions about common underlying mechanisms.
| 633
DISTEFANO AND GLADING the reported developmental window for Ccm2 deletion required to form CCM lesions. 7 Angiogenesis is driven by the expression and activity of vascular endothelial growth factor (VEGF), a pro-mitotic and pro-migratory growth factor intimately linked with endothelial activation and angiogenesis. Notably, human CCM lesions have been shown to exhibit increased expression of VEGF, supporting the idea that VEGF may play a role in the pathogenesis of this disease, 8, 9 as has been suggested for other types of vascular malformations, including hereditary haemorrhagic telangiectasia. 10, 11 Furthermore, the abnormal morphology and increased permeability of CCM lesions is highly similar to that seen when VEGF is overexpressed in vivo. 12, 13 Our previous work using an endothelial cell-based tissue culture model showed that loss of Krit1 and Ccm3 stimulated the expression of VEGF. The increase in VEGF expression led to activation of VEGFR2 and subsequent increased endothelial monolayer leak, stress fibre formation, migration and phosphorylation of VEcadherin and β-catenin-events required for angiogenesis and which could contribute to CCM lesion formation. Inhibition of VEGFR2 was able to acutely reverse increased microvessel permeability in Krit1 +/− mice, 14 supporting the idea that the VEGF pathway is up-regulated in intact Krit1 deficient vessels in vivo.
We hypothesized that VEGF signalling could contribute to the initiation and progression of CCM in vivo. In this study, we examined whether VEGF signalling contributes to CCM development. Using an inducible KRIT1 endothelial-specific knockout mouse that models CCM, we show that VEGFR2 activation plays a role in CCM pathogenesis, as inhibition of VEGFR2 kinase activity reduced the number of lesions formed. More remarkable, VEGFR2 inhibition completely blocked microvessel permeability and significantly decreased the appearance of haemorrhage from lesions. Finally, we show that loss of both CCM2 and CCM3 also increases tyrosine phosphorylation of VEGFR2, suggesting that VEGFR2 activation may be a common mechanism that enhances the severity of CCM formation.
| MATERIAL S AND ME THODS

| Mouse models
Mice were bred and maintained under standard conditions in the University of Rochester animal facilities, which are accredited by the American Association for Accreditation of Laboratory Animal Care.
All protocols were approved by the institutional review board.
Mice with a conditional (floxed) allele for Krit1, a germline deleted Krit1 allele and the endothelial inducible Cre recombinase (PDGFB-iCreER T2 ) have been described. 5, 15 Cre recombinase activity was induced by administration of a single injection of tamoxifen and PDGFB-iCreER T2 ; Krit1 flox/+ littermate controls, were injected ip with 3 mg/kg SU5416 dissolved in corn oil (TOCRIS/R&D), or vehicle (corn oil), twice weekly, starting at P14. Treatment continued until the mice were four months of age, at which time the animals were sacrificed and perfused via the right ventricle with PBS, followed by perfusion of 3.7% formaldehyde to fix the tissue. Alternatively, male animals were prepared for intravital microscopy as described, then sacrificed and perfused.
| Microvascular brain endothelial cell isolation
Microvascular endothelial cells were isolated from the brains of SU5416 and vehicle-treated Krit1 ieKO and control mice. Briefly, brain tissues were homogenized and then digested with 1 mg/mL collagenase A (Roche), 25 U/mL DNase (Roche) and 50 μg/mL gentamycin at 37°C for 1.5 hours, with mixing every 15 minutes. Non-myelinated cells were pelleted through 20% BSA at 1000 g for 20 minutes. The cell pellet was then digested with 1 mg/mL collagenase-dispase and 
| Intravital microscopy
Preparation and visualization of the cremaster muscle, as well as measurement of permeability to Alexa-488 bovine serum albumin (BSA, Invitrogen), was performed as previously described. 14, 16 The vascular wall permeability (P s , cm/s) is calculated from the measured flux per unit microvessel surface area at a known BSA concentration gradient with corrections for the source volume and surface area due to the confocal slice. 17 Images were acquired from at least 15 vessel sites, which is the appropriate determinant for n in these experiments. Data are given as combined microvessel permeability (arteriole and venule). Data were analysed using one-way ANOVA with Bonferroni post hoc testing.
| Fluorescein permeability assay
Ten milligrams sodium fluorescein in 0.1 mL sterile saline was injected i.p. 45 minutes prior to analysis. Serum and brain tissue were collected and assayed for fluorescein fluorescence, following trichloroacetic acid extraction and subsequent neutralization, using a BioTek Synergy H4 plate reader. Samples were compared to a standard curve of sodium fluorescein.
| Histology
Two-millimetre serial coronal sections of formaldehyde fixed brains were prepared and imaged using Mantis Elite HD dissecting scope (Vision Engineering) to assess total lesion number and size. Total lesion number was measured from images of the anterior plane of each 2 mm section by an investigator blind to sample identity. Lesion size was directly calculated from the image using NIH Image. The third and seventh section of each brain (anterior-posterior) was then further processed for paraffin embedding and thin sectioning. Three 5-μm serial sections were taken at 100 μm steps from the embedded coronal slices and stained with haematoxylin/eosin (general histology) and potassium ferrocyanide/nuclear fast red (free iron) as described previously. 5, 18 Images were captured at room temperature using Infinity Capture software (Lumenera) with an UPLSAPO 10× (n.a. 0.30) objective on an Olympus IX70 microscope, and an Infinity 2 camera (Lumenera). Non-targeting negative control siRNA #1 and anti-KRIT1 siRNA were obtained from Invitrogen (AM16708, Ambion/Invitrogen); CCM2 and CCM3 siRNAs were obtained from Dharmacon.
| Cell culture and transfection
| VEGF enzyme-linked immunoassay (ELISA)
ELISA high binding plates (Thermo Fisher Scientific) were coated with 1 μg/mL of mouse anti-VEGF (R&D Biosystems) in phosphatebuffered saline (PBS) overnight at room temperature. Plates were then blocked with 300 μL of blocking buffer (1% BSA in PBS) for 1 hour at room temperature. After washing with wash buffer (PBS with 0.2% Tween-20), 100 μL samples of conditioned medium from siRNA-transfected 60 mm plates were added to appropriate wells and incubated at room temperature for 2 hours. A standard curve of recombinant VEGF from 0 to 2000 pg/mL was run alongside experimental samples. Plates were washed again and incubated with 1.2 μg/mL goat anti-VEGF (R&D) for 2 hours at room temperature.
After washing, streptavidin-horseradish peroxidase (HRP, Thermo Fisher Scientific) was added for 1 hour followed by detection with 3,3′,5,5′-tetramethylbenzidine (TMB, eBioscience). Data were analysed using one-way ANOVA with Tukey's post hoc testing.
| Immunoprecipitation and western blotting
HPAEC or mouse brain microvascular cell lysates were prepared in MgALB150 lysis buffer (50 mmol/L Tris pH 7.4, 150 mmol/L NaCl, 0.5% NP-40, 5 mmol/L MgCl 2 , phosphatase and protease inhibitors). Protein quantification was performed using a bicinchoninic acid assay kit (Thermo Fisher), and equivalent amounts of total cell protein were added to tubes containing 2 μg monoclonal rabbit anti-VEGFR2 and 20 μL of protein G-Sepharose beads. After incubation at 4°C overnight, immunoprecipitated proteins were blotted against phospho-tyrosine (Cell Signaling) and then re-probed with anti-VEGFR2 to assess precipitation efficiency. Alternatively, lysates were directly probed with rabbit anti-phosphoY1175 VEGFR2 (Thermo Fisher Scientific), followed by incubation of secondary antibody (goat anti-rabbit DyLight-800 (Fisher)). An Odyssey Infrared Imaging System (LI-COR Biosciences) was used to image membranes and for densitometry.
| Statistics
Statistical analysis (ie one-way ANOVA with appropriate post hoc testing) was performed using PRISM software (version 4.0, GraphPad Software Inc). Statistical significance was assessed assuming a .05 significance level and a two-sided alternative hypothesis.
| RE SULTS
| VEGFR2 inhibition reduces lesion number in Krit1 endothelial knockout mice
Our in vitro data strongly support the idea that VEGF is a critical player in the development of CCM. To test this directly, we utilized Krit1 ieKO mice, which develop lesions similar to those seen in human CCM patients. 15 Tamoxifen injection of PDGFB-iCreER T2 Krit1 flox/ flox mice at P1 stimulates endothelial-specific Cre-mediated recombination and loss of Krit1 protein in >90% of the endothelium. In these animals, Type 1 lesions (enlarged vessels with a single lumen but no apparent haemorrhage) are visible to the naked eye in >90% of animals at 2 weeks of age ( Figure S1 ). Mature multi-cavern lesions are found in 100% of animals at 3 months, and death occurs around 5 months of age (data not shown). To test whether VEGF signalling downstream of loss of Krit1 is involved in CCM pathogenesis, we treated Krit1 ieKO mice with 3 mg/kg of the VEGFR2 inhibitor SU5416 twice weekly until 4 months of age, starting at P14. SU5416 (Semaxinib) is a potent and effective VEGFR2 kinase inhibitor and has been shown to inhibit angiogenesis in several in vivo models. [19] [20] [21] KRIT1 ieKO mice exhibited increased pY1175 VEGFR2 levels in cerebral endothelial cells compared to their wild-type counterparts, which was reversed following SU5416 treatment ( Figure 1A) , demonstrating the effectiveness of the inhibitor in vivo. Animals treated with SU5416 exhibited higher weights ( Figure 1B 
| VEGFR2 inhibition does not limit lesion size
Previous studies have linked lesion size to the progression of CCM, as smaller lesions in the human population appear less likely to become haemorrhagic/symptomatic. 2 Indeed, Krit1 ieKO mice as well as Ccm2 and Ccm3-dependent mouse models of CCM show a range of lesion size and complexity. 5 There was no statistical difference in average lesion size in SU5416-treated Krit1 ieKO mice compared to vehicle control (Figure 2A) , and the distribution of lesion sizes was roughly equivalent ( Figure 2B ). Thus, while inhibition of VEGFR2 decreases the number of lesions, it does not significantly affect the distribution of lesion size, suggesting that VEGF may be more important for the initiation, but not the growth, of CCM lesions.
| VEGFR2 inhibition blocks vascular permeability in Krit1 ieKO mice
One of the most debilitating aspects of CCM is haemorrhagic stroke caused by chronic or acute blood leakage from lesions. 2 Our previous work indicated that inhibition of VEGF signalling in KRIT1 hemizygous cells and animals could acutely restore permeability to control levels. 14 Figure 3A) . As CCM lesions predominate in the central nervous system, though clearly the effect on vessel integrity extends beyond the brain in our mouse model, we also investigated whether VEGF inhibition affected the permeability of fluorescein in the brains of KRIT1 deficient mice. Krit1 ieKO animals exhibited a 63% increase in the permeability of fluorescein versus control animals, which was reversed by treatment with SU5416 ( Figure 3B ).
| VEGFR2 inhibition reduces lesion haemorrhage
As increased permeability may contribute to the rate of haemorrhage in CCM lesions, we next wanted to assess the appearance of haemorrhage in the lesions of vehicle and SU5416 treated animals.
Haemorrhage in human and mouse CCM lesions can be observed by staining for free iron, a product of extravascular red blood cell lysis.
We observed a significant decrease in the appearance of free iron in the lesions of SU5416 treated Krit1 ieKO animals (0.11% ± 0.02) when compared to vehicle-treated Krit1 ieKO (0.24% ± 0.04, Figure 4A,B) . In addition, the extent of iron staining in vehicle-treated animals greatly exceeded that of SU5416 treated animals, suggesting that the total extent of haemorrhage was severely limited by the inhibition of VEGFR2 ( Figure 4C ). As larger lesions are thought to be more likely to haemorrhage, we assessed whether the reduction in iron-positive lesions was due to a reduction in the number of larger lesions by examining the size distribution of lesions that were iron positive. In vehicle-treated Krit1 ieKO mice, iron-positive lesions had an average diameter of 0.14 ± 0.02 mm. However, in SU5416 treated Krit1 ieKO , the majority of iron-positive lesions were larger (0.19 ± 0.02). This is clearly shown as a shift in the median size of iron-positive lesions ( Figure 4D ), suggesting that inhibition of VEGF/VEGFR2 activation decreases the likelihood of haemorrhage of small to medium lesions, but not large lesions, a potentially clinically significant finding.
| Loss of all CCM protein family members increases VEGFR2 tyrosine phosphorylation
An association between the genetic loss of CCM proteins and VEGF signalling has previously been suggested, though the mechanism underlying this connection remained unclear. We recently found that loss of KRIT1 and CCM3 in vitro induces an increase in VEGF mRNA via increased ß-catenin/TCF-dependent nuclear transcription. In KRIT1 depleted cells, the subsequent increase in VEGF protein and activation of VEGFR2 contributed to an activated endothelial phenotype with several hallmarks of angiogenic endothelium. 14 As the up-regulation of VEGF mRNA led to increased VEGFR2 activation in KRIT1 depleted cells, we predicted a similar effect in CCM3 but not CCM2 depleted endothelial cells, which did not up-regulate VEGF mRNA. 14 Interestingly, independent knockdown of both CCM3 and CCM2 elevated tyrosine phosphorylation of VEGFR2 in human pulmonary artery endothelial cells ( Figure 5A ,B and Figure S2 ), but did not increase VEGF secretion ( Figure 5C ). These data suggest that VEGFR2 activation may be a common signalling mechanism in CCM development, though the mechanisms are likely divergent.
| D ISCUSS I ON
Blocking endogenous VEGFR2 activation significantly reduced the number of lesions that formed within the brain of Krit1 deficient animals (Figure 1 ). Our previous study demonstrated the presence of a feed-forward mechanism whereby loss of KRIT1 caused increased nuclear β-catenin transcriptional activity, increased expression of VEGF and activation of VEGFR2 to promote loss of barrier function, migration, etc. We have now shown that the activation of VEGFR2 is a common mechanism downstream of depletion of all three CCM proteins ( Figure 5A ). This was surprising in light of our previous finding that CCM2 knockdown showed no significant increase in VEGFA mRNA, and though CCM3 knockdown did increase VEGFA mRNA, 14 it did not increase VEGF protein secretion ( Figure 5C ). However, the clear presence of activated VEFGR2 in CCM2 and CCM3 deficient cells suggests that an alternative mechanism exists to promote receptor activation downstream of loss of these proteins. One such mechanism was reported by You et al who showed that down-regulation of Dll4/ Notch signalling in CCM3 depleted endothelial cells increased VEGF and VEGFR2 expression. 22 However, another study found that VEGFR2 activity was diminished in the absence of CCM3. 23 These discrepancies may be due to experimental differences (ie knockdown level, activation/inactivation of specific tyrosines on VEGFR2) and remain to be reconciled. Alternatively, recent reports have demonstrated a role for inflammatory signalling and oxidative stress in CCM lesion development, including the up-regulation of the oxidative stress-responsive transcription factor Nrf2, 24 F I G U R E 5 Loss of CCM protein family members increases VEGFR2 tyrosine phosphorylation. A, Tyrosine phosphorylation of VEGFR2 in HPAEC transfected with negative control (NC), anti-KRIT1, anti-CCM2 and anti-CCM3 siRNA. IB, immunoblot; IP, immunoprecipitation. Blots are representative, n = 3. B, Densitometric quantification of blots in (A). Data shown are P-Tyr normalized to total VEGFR2, ± SEM, P = .0223 by ANOVA, *P < .05 by post hoc testing vs NC transfected cells. C, VEGF protein (pg/mL) in conditioned media harvested from cells expressing anti-KRIT1, anti-CCM2 and anti-CCM3 siRNA P = .032 by ANOVA, *P < .05 by post hoc testing vs NC transfected cells which indirectly promotes VEGF expression. 25 Furthermore, Tang et al noted that activation of Toll-like receptor-4 (TLR4) signalling by blood-borne gram-negative bacteria led to greater CCM lesion burden in a mouse model of CCM. 26 In addition to activation of TLR4, infection with gram-negative bacteria can be associated with increased expression of VEGF. 27, 28 Our data are consistent with these observations. Though more work needs to be done to elaborate the mechanism underlying VEGFR2 activation in the absence of CCM proteins, our work supports the potential impact of VEGF signalling induced by infection as an important disease modifier and opportunity for therapeutic intervention.
Our data strongly suggest that activation of VEGF signalling could be a common element of CCM pathogenesis. This suggests that angiogenic environmental signals, perhaps combined with cell autonomous changes in gene expression, fundamentally alter the phenotype of the endothelium to cause lesion genesis. However, activation of VEGF signalling could also contribute to the variation in the clinical presentation of CCM, or the progression of the disease.
Local differences in the activation of VEGF signalling could provide the necessary context for lesion development. However, this fails to specifically address the stochastic development of lesions, which could be due to changes in other genetic modifiers or local sensitivity to vascular stress. [29] [30] [31] [32] Strikingly, inhibition of VEGFR2 completely blocked the increase in endothelial permeability caused by loss of Krit1, which translated into a significant decrease in haemorrhage from lesions. These data support the idea, as suggested by clinical studies, that VEGF could be a prognostic indicator of haemorrhage risk in CCM patients. On the other hand, VEGF inhibition had no effect on the distribution of lesion size, indicating that this mechanism likely does not affect the growth or expansion of CCM lesions. To be effective, a potential treatment should affect at least one of the three key features of CCM disease: lesion initiation, lesion growth or lesion haemorrhage. Our data strongly suggest that inhibition of VEGFR2 can address lesion formation and haemorrhage, 2 of the 3 cardinal features.
The inability to fully block lesion formation in vivo may alternatively reflect the need to manipulate several pathways simultaneously, though which pathways to select remains an elusive answer.
Intriguingly, several of the pathways modified following loss of KRIT1 (or CCM2) are known to crosstalk with VEGF signalling. For example, loss of both KRIT1 or CCM2 increases phosphorylation of ERK1/2, 33, 34 which is also activated downstream of VEGFR2. 35 Also, loss of KRIT1 or CCM2 leads to an increase in active c-Jun N-terminal kinase (JNK). 31 The activation of JNK in KRIT1 depleted cells is mediated by reactive oxygen species, which can be activated by VEGF signalling, 36 or activate VEGF signalling. 37 More studies to outline the hierarchy of these pathways will be necessary before we can determine whether all should be targeted, or whether, for example, VEGF signalling could be targeted as a common mediator, as is suggested by our data.
These observations have important implications for the therapeutic approach to CCM disease. Currently, the mainstay of therapy for CCM is surgical excision or radiological destruction of the lesion.
There are now several potential therapeutic approaches suggested to impact CCM lesion pathophysiology, and it is hoped that a new era of medical management of CCM will prove beneficial. Anti-angiogenic therapy may prove useful to prevent or delay lesion formation, or to stabilize the haemorrhage prone lesion and may form part of a multi-pronged medical approach to the treatment of CCM.
